These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27013496)

  • 1. Changes in coagulation functions and hemorheological parameters may predict hematoma formation after total knee arthroplasty.
    Liu N; Luo S; Hang C; Zha Z; Li J; Wu W; Hou D
    J Orthop Surg Res; 2016 Mar; 11():35. PubMed ID: 27013496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and efficacy of rivaroxaban for prevention of deep vein thrombosis in patients with preoperative abnormal D-dimer after total knee arthroplasty].
    Sun Yunbo ; Wang Lei ; Shen Xingqin ; Zhang Dongliang ; Liu Jun ; Sun Zhenhui
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2014 Aug; 28(8):955-9. PubMed ID: 25417306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux.
    Izushi Y; Takami Y; Shiota N; Tetsunaga T; Ookura Y; Shimada K; Egawa T; Kiuchi T; Sato T; Takuma R
    Biol Pharm Bull; 2016; 39(4):516-23. PubMed ID: 27040624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Blood Loss between Open-Box Prosthesis and Closed-Box Prosthesis after Primary Total Knee Arthroplasty.
    Ma Q; Sun CJ; Wu S; Cai X
    Orthop Surg; 2021 May; 13(3):768-777. PubMed ID: 33666377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.
    Helin TA; Virtanen L; Manninen M; Leskinen J; Leppilahti J; Joutsi-Korhonen L; Lassila R
    J Thromb Thrombolysis; 2017 May; 43(4):562-569. PubMed ID: 28315166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How the direct oral anticoagulant apixaban affects thrombin generation parameters.
    Tripodi A; Padovan L; Veena C; Scalambrino E; Testa S; Peyvandi F
    Thromb Res; 2015 Jun; 135(6):1186-90. PubMed ID: 25895845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
    Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
    Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
    J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of thrombelastography in primary total knee and total hip replacement: a prospective 87 patients study.
    Wang C; Liu Q; Sun L; Dai G
    Blood Coagul Fibrinolysis; 2019 Sep; 30(6):281-290. PubMed ID: 31369408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
    Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
    Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
    Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
    J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
    Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
    Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study on role of tranexamic acid in reducing postoperative blood loss in total knee arthroplasty and its effect on coagulation profile.
    Dahuja A; Dahuja G; Jaswal V; Sandhu K
    J Arthroplasty; 2014 Apr; 29(4):733-5. PubMed ID: 24184325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial.
    Liu X; Thompson J; Phatak H; Mardekian J; Porcari A; Johnson M; Cohen AT
    Thromb Haemost; 2016 Jan; 115(1):161-8. PubMed ID: 26446706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation.
    Pawlicki J; Cierpka L; Król R; Ziaja J
    Transplant Proc; 2011 Oct; 43(8):3013-7. PubMed ID: 21996213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.